HANK & LIN'S GROUP

The past is prologue and the future is scintillating

18F-P16-093

Introduction to [18F]AlF-PSMA-093 (P16-093): 

[18F]AlF-PSMA-093 is a novel PSMA-targeted PET imaging agent developed for the detection and management of prostate cancer. It is labeled with Fluorine-18 (18F) using the Aluminum Fluoride (AlF) chelation method, providing a stable and efficient radiolabeling approach that enhances its clinical applicability.

With its high affinity for Prostate-Specific Membrane Antigen (PSMA), [18F]AlF-PSMA-093 enables sensitive and specific imaging of primary tumors, metastatic lesions, and recurrent disease in prostate cancer patients. Compared to traditional Gallium-68 (68Ga)-based PSMA tracers, [18F]AlF-PSMA-093 offers several advantages, including:

  • Longer half-life (110 minutes), allowing for extended imaging windows and centralized production with regional distribution.
  • Superior image resolution, aiding in the detection of smaller lesions and early-stage prostate cancer.
  • Greater availability, as 18F can be produced in cyclotrons and transported to multiple imaging centers.

These attributes make [18F]AlF-PSMA-093 an attractive choice for widespread clinical use, particularly in high-volume medical centers and multi-center imaging networks. By combining PSMA-targeted specificity with the logistical and imaging advantages of Fluorine-18, this next-generation radiopharmaceutical has the potential to improve prostate cancer diagnosis, staging, and treatment monitoring, ultimately advancing precision oncology in patient care.


Publications:

  1. Zhao, Ruiyue, et al. "First-in-human study of PSMA-targeting agent,[18F]AlF-P16-093: dosimetry and initial evaluation in prostate cancer patients." European Journal of Nuclear Medicine and Molecular Imaging51 (2024): 1753-176. https://doi.org/10.1007/s00259-024-06596-y
  2. Zhao, Ruiyue, et al. “Determining the optimal pharmacokinetic modelling and simplified quantification method of [18F]AlF-P16-093 for patients with primary prostate cancer (PPCa)”.European Journal of Nuclear Medicine and Molecular Imaging 51(2024):2124–2133. https://doi.org/10.1007/s00259-024-06624-x
  3. Alexoff, D., Choi, S.R., Ploessl, K.et al.Optimization and scale up of production of the PSMA imaging agent [18F]AlF-P16-093 on a custom automated radiosynthesis platform. EJNMMI radiopharm. chem.9, 15 (2024).

    https://doi.org/10.1186/s41181-024-00247-1

  4. Zha, Z., Choi, S.R., Ploessl, K., Alexoff, D., Zhao, R., Zhu, L. and Kung, H.F., "Radiolabeling optimization and preclinical evaluation of the new PSMA imaging agent [18F]AlF-P16-093." Bioconjugate Chemistry 32.5 (2021): 1017-1026. https://doi.org/10.1021/acs.bioconjchem.1c00177


Meeting Abstracts：

  1. Alexoff, David, Seokye Choi, Karl Ploessl, Dohyun Kim, Ruiyue Zhao, Lin Zhu, and Hank Kung. "Large scale production of the PSMA imaging agent [18F]AlF-P16-093 on a custom automated radiosynthesis platform." Journal of Nuclear Medicine 65 (supplement 2), (2024): 241116.
  2. Ke M, Zhao R, Lv J, Alexoff D, Ploessl K, Zhu L, Kung HF, Wang X. Head-to-head comparison of [18F]AlF-PSMA-093 and [18F]AlF-PSMA-BCH PET/CT in prostate cancer diagnosis. Journal of Nuclear Medicine 65 (supplement 2), 241116.  https://jnm.snmjournals.org/content/65/supplement_2/241402/tab-article-info